alexa Systems Pharmacological Approach For A Rationally Derived Sequential Combination Therapy To Enhance The Delivery And Efficacy Of Monoclonal Antibodies Into Solid Tumors
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

14th World Cancer & Anti-Cancer Therapy Convention
November 21-23, 2016 Dubai, UAE

Sihem Bihorel
University of Florida, USA
Posters & Accepted Abstracts: J Cancer Sci Ther
DOI: 10.4172/1948-5956.C1.094
Abstract
HER2-positive breast cancer (BC) is fast-growing and more aggressive than other types of BC. Trastuzumab (TZM), an anti-HER2 receptor humanized monoclonal antibody, is used in BC in combination with paclitaxel (PAC) in a 24 h sequence treatment during the first week followed by a simultaneous administration thereafter. There is no scientific rationale for such therapeutic regimen. Here we propose to utilize a proteomics approach to optimize the sequential combination of PAC+TZM to enhance their anti-tumoral activity, and hence patients’ outcome. Six therapeutic regimens were investigated in vitro on BT474 cells: A human BC cell line overexpressing HER2 receptor, including PAC and TZM alone at 50 and 100 nM, a tumor priming regimen (TPR) with PAC given 24 h prior to TZM, a reverse-TPR, a concurrent regimen and a vehicle as a control. Proteomics analysis was conducted in each regimen and several identified key signaling proteins in the PAC+TZM pathway were measured over time, including p21, p27, ERK1,2, JNK1,2, and cleaved-PARP. TPR showed more amplified proteins dynamic responses compared to others with: 1) Continuous activation of p21 and p27, both are hallmark biomarkers for the cell-cycle arrest response, and 2) down regulation of HER2 survival pathways mediated via ERK1,2 and JNK1,2. A more efficacious ADCC and a sustained apoptotic response were also observed. TPR elicits synergistic interactions in vitro. The underlying mechanisms involve increased apoptosis, cell-cycle arrest, and antibody-dependent cellular cytotoxicity. The proposed research will develop and employ a systems pharmacology model to design optimal regimens for the association (PAC+TZM) in HER2-positive BC.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords